DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM)

 

Abstract No : 8502

Abstract Type : Oral Abstract Session

Indication : Multiple Myeloma

Intervention : Belantamab mafodotin

Company : GlaxoSmithKline

Technology : BCMA Inhibitor

 

Results:

As of February 6, 2020, 52 patients were enrolled: 6 patients were enrolled at 2.5 mg/kg single dose and 7 at 3.4 mg/kg single dosing in Part 1, and 45 patients in Part 2. No dose-limiting toxicities were observed. Corneal events (including keratopathy, blurred vision, and dry eye) and thrombocytopenia were the most frequently reported AEs and were clinically manageable.

 

Conclusion:

In DREAMM-6, preliminary data demonstrate that the combination of belantamab mafodotin and BorDex has an acceptable safety profile, with no new safety signals identified. Funding: GlaxoSmithKline (207497). Drug linker technology licensed from Seattle Genetics; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.

 

Commentary:

Huge potential for belantamab mafodotin as combination therapy in patients with earlier stages of multiple myeloma agent owing to its promising response data and acceptable safety profile

Note: In recent years, the blood disorder space has seen a surge in growth owing to the increase in RRMM clinical trials, along with the rising healthcare spending and increase in disease awareness. As a result, both the Relapsed/refractory Multiple Myeloma market and the multiple myeloma market are anticipated to grow significantly in the coming years.